Astrazeneca plc ADR (NASDAQ: AZN) Down -0.15% This Year: What To Expect Next

The trading price of Astrazeneca plc ADR (NASDAQ:AZN) closed lower on Monday, April 01, closing at $67.25, -0.74% lower than its previous close.

The company’s P/E ratio in the trailing 12-month period was 35.24, while its 5Y monthly beta was 0.17. In examining the 52-week price action we see that the stock hit a 52-week high of $76.56 and a 52-week low of $60.47. Over the past month, the stock has gained 4.82% in value.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Astrazeneca plc ADR, whose market valuation is $208.50 billion at the time of this writing. The dividend yield on the company stock is 2.16%, while its Forward Dividend ratio is 1.45. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by $1.25 per share this quarter, however they have predicted annual earnings per share of $3.88 for 2024 and $4.38 for 2025. It means analysts are expecting annual earnings per share growth of 6.90% this year and 12.90% next year.

Analysts have forecast the company to bring in revenue of $12.01 billion for the current quarter, with the likely lows of $11.76 billion and highs of $12.44 billion. The average estimate suggests sales will likely up by 13.80% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2024 is $50.76 billion. The company’s revenue is forecast to grow by 10.80% over what it did in 2024.

A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Astrazeneca plc ADR 1 upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest AZN has a 50% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a Hold, while an average of long term indicators suggests that the stock is currently 50% Buy.

If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 2.69, which symbolizes a positive outlook. A quick review shows that AZN’s price is currently 1.41% off the SMA20 and 2.36% off the SMA50. The RSI metric on the 14-day chart is currently showing 56.39, and weekly volatility stands at 1.35%. When measured over the past 30 days, the indicator reaches 1.19%. Astrazeneca plc ADR (NASDAQ:AZN)’s beta value is currently sitting at 0.51, while the Average True Range indicator is currently displaying 0.99.

To see how Astrazeneca plc ADR stock has been performing in comparison to its peers in the industry, here are the numbers: AZN stock’s performance was -0.74% in the latest trading, and -2.03% in the past year. Astrazeneca plc ADR has a P/E ratio of 35.24.

An evaluation of the daily trading volume of Astrazeneca plc ADR (NASDAQ:AZN) indicates that the 3-month average is 6.29 million. However, this figure has increased over the past 10 days to an average of 4.59 million.

Currently, records show that 3.10 billion of the company’s shares remain outstanding. The insiders hold 0.03% of outstanding shares, whereas institutions hold 15.98%. The stats also highlight that short interest as of Mar 15, 2024, stood at 9.26 million shares, resulting in a short ratio of 1.87 at that time. From this, we can conclude that short interest is 0.34% of the company’s total outstanding shares. It is noteworthy that short shares in March were up slightly from the previous month’s figure, which was 8.92 million. However, since the stock’s price has seen -0.15% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.